Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Baxter International ( (BAX) ) has issued an update.
On May 6, 2025, Baxter International Inc. held its 2025 Annual Meeting, where a quorum of approximately 93.9% was achieved with 481,459,559 shares represented. The meeting resulted in the election of ten directors, approval of executive compensation for 2024, and ratification of PricewaterhouseCoopers LLP as the independent auditor for 2025. However, a stockholder proposal regarding executives retaining significant stock was not approved.
Spark’s Take on BAX Stock
According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.
Baxter International’s stock score reflects significant financial challenges, including declining revenue and cash flow issues, despite some improvement in debt management. Technical indicators suggest a cautious outlook, with the stock trading below key moving averages. On the positive side, recent earnings surpassed expectations, and strategic initiatives may enhance future performance. However, valuation concerns remain due to a negative P/E ratio.
To see Spark’s full report on BAX stock, click here.
More about Baxter International
Baxter International Inc. operates in the healthcare industry, focusing on providing essential medical products and services. The company is known for its innovative solutions in critical care, nutrition, renal, hospital, and surgical care, catering to a global market.
Average Trading Volume: 5,025,705
Technical Sentiment Signal: Strong Sell
Current Market Cap: $15.35B
For an in-depth examination of BAX stock, go to TipRanks’ Stock Analysis page.